Fyrwald J Erik 4

What Happened

• J. Erik Fyrwald, listed as a director of Eli Lilly & Co. (LLY), was credited with an award/acquisition of 9.572 shares (stock units) on 2026-02-17. The filing reports a per-share value of $1,036.05, for a total reported value of approximately $9,917.
• This transaction is coded as an award/grant (A) rather than an open-market purchase or sale.

Key Details

• Transaction date: 2026-02-17; reported on Form 4 filed 2026-02-18 (appears timely).
• Price/value: 9.572 shares × $1,036.05 = ~$9,917.
• Shares owned after transaction: not specified in the provided filing.
• Footnote: At Fyrwald’s election, the shares were deferred in lieu of cash under the Lilly Directors' Deferral Plan and will be settled in shares of common stock following his separation from service.
• No indication of a 10b5-1 plan, sale, or tax-withholding event in this filing.

Context

• This was a director compensation award (deferred stock units), which is routine for board members and does not reflect an open-market buy or sell decision.
• Deferred stock units are typically settled into actual shares later (here, upon separation), so there was no immediate sale or cashless exercise tied to this grant.